Vol 48 No 1

What advances in urology do you hope to see in 2020?

December 23, 2019

“It’s actually an exciting time for patients who have metastatic urothelial cancers and prostate cancers or advanced prostate cancers because there are a lot more products on the way, like the newer hormone agents for prostate cancer and the new immunologic agents like PARP inhibitors for different types of cancers," says one urologist.

IPP suit hinges on expert’s lack of credibility

January 02, 2020

"The expert testified that the standard of care after penile prosthesis surgery is to leave the implant in a semi-inflated state for 4 to 6 weeks, when in fact the standard is to keep the implant in a deflated state," writes Brianne Goodwin, JD, RN.

Biofeedback training code deleted, replaced with time-based codes

January 03, 2020

"By creating time-based codes, one can most accurately describe and be reimbursed for the amount of time and effort spent face to face with an individual patient," writes Jonathan Rubenstein, MD, and Mark Painter.

The physician executive: How one urologist balances MD, CEO roles

January 07, 2020

In this interview, physician executive J. Christian Winters, MD, outlines his multiple professional roles, explains how he divides his time between clinical and administrative responsibilities, and offers advice to young urologists seeking a career in leadership.

Pain-focused stone patients less likely to reach treatment goals

January 08, 2020

Patients with kidney stones who rank their pain at the maximum level on a 100-point scale or whose number-one goal for treatment is to relieve pain are less likely to reach their treatment goals than other patients undergoing kidney stone treatment, a recent study found.

OnabotA use on the rise for neurogenic bladder

January 10, 2020

“Although the raw number of augmentations and diversions have been relatively unchanged, the proportion of patients undergoing both surgeries declined while the proportion of patients undergoing Botox injections doubled over the past 5 years,” said Rita P. Jen, MD, MPH.

Pembrolizumab granted new bladder Ca indication

January 14, 2020

The FDA has approved the anti-PD-1 therapy pembrolizumab (KEYTRUDA) as monotherapy for the treatment of patients with Bacillus Calmette-Guerin-unresponsive, high-risk, nonmuscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

FDA approves enfortumab for locally advanced or metastatic urothelial Ca

January 14, 2020

The FDA has granted accelerated approval to enfortumab vedotin-ejfv (PADCEV) for the treatment of adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1 inhibitor and a platinum-containing chemotherapy before or after surgery or in a locally advanced or metastatic setting.

Protocol cuts narcotic use in IPP patients

January 15, 2020

Researchers studying a novel multimodal analgesia protocol at multiple institutions in the U.S. for patients having penile implant surgery found narcotic prescriptions before, during, and in the post-surgery recovery period fell from as high as 50 to 60 narcotic pills to 10 to 15 pills.